Moomoo AI 已提取核心信息
Agilent Technologies, a leading company in the diagnostics and genomics sector, has announced a significant reorganization of its business segments. The company has moved its Cell Analysis Division from the Life Sciences and Applied Markets Group (LSAG) to the Diagnostics and Genomics Group (DGG) as of December 20, 2023. This strategic move aims to enhance growth opportunities for both segments. Despite the reorganization, Agilent will maintain its three business segments: LSAG, DGG, and Agilent CrossLab, all of which will continue to be reportable segments. The company will present its financial statements reflecting the new structure starting with the quarter ending January 31, 2024, with prior periods being recast to align with the changes. This information was disclosed in a Current Report on Form 8-K filed with the SEC, which includes selected segment information and is not intended for filing purposes under Section 18 of the Securities Exchange Act of 1934, nor is it to be incorporated by reference into any registration statement or other document.
Agilent Technologies, a leading company in the diagnostics and genomics sector, has announced a significant reorganization of its business segments. The company has moved its Cell Analysis Division from the Life Sciences and Applied Markets Group (LSAG) to the Diagnostics and Genomics Group (DGG) as of December 20, 2023. This strategic move aims to enhance growth opportunities for both segments. Despite the reorganization, Agilent will maintain its three business segments: LSAG, DGG, and Agilent CrossLab, all of which will continue to be reportable segments. The company will present its financial statements reflecting the new structure starting with the quarter ending January 31, 2024, with prior periods being recast to align with the changes. This information was disclosed in a Current Report on Form 8-K filed with the SEC, which includes selected segment information and is not intended for filing purposes under Section 18 of the Securities Exchange Act of 1934, nor is it to be incorporated by reference into any registration statement or other document.
诊断和基因组学领域的领先公司安捷伦科技宣布对其业务部门进行重大重组。自2023年12月20日起，该公司已将其细胞分析部门从生命科学与应用市场集团（LSAG）移至诊断和基因组学组（DGG）。这一战略举措旨在增加这两个细分市场的增长机会。尽管进行了重组，但安捷伦仍将维持其三个业务领域：LSAG、DGG和安捷伦CrossLab，所有这些业务部门都将继续是可申报的细分市场。从截至2024年1月31日的季度开始，该公司将提交反映新结构的财务报表，并对前几期进行了重组以适应变化。这些信息是在向美国证券交易委员会提交的表格8-K的最新报告中披露的，该报告包括选定的分部信息，不用于1934年《证券交易法》第18条规定的申报目的，也不得以引用方式纳入任何注册声明或其他文件中。
诊断和基因组学领域的领先公司安捷伦科技宣布对其业务部门进行重大重组。自2023年12月20日起，该公司已将其细胞分析部门从生命科学与应用市场集团（LSAG）移至诊断和基因组学组（DGG）。这一战略举措旨在增加这两个细分市场的增长机会。尽管进行了重组，但安捷伦仍将维持其三个业务领域：LSAG、DGG和安捷伦CrossLab，所有这些业务部门都将继续是可申报的细分市场。从截至2024年1月31日的季度开始，该公司将提交反映新结构的财务报表，并对前几期进行了重组以适应变化。这些信息是在向美国证券交易委员会提交的表格8-K的最新报告中披露的，该报告包括选定的分部信息，不用于1934年《证券交易法》第18条规定的申报目的，也不得以引用方式纳入任何注册声明或其他文件中。
有用
没用